- Home
- CTO vs EYPT Comparison
CTO vs EYPT Comparison
Compare CTO & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CTO | EYPT |
|---|---|---|
| Founded | 1902 | 1987 |
| Country | United States | United States |
| Employees | 42 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Laboratory Analytical Instruments |
| Sector | Real Estate | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 643.7M | 1.5B |
| IPO Year | N/A | 2005 |
Fundamental Metrics
Financial Performance| Metric | CTO | EYPT |
|---|---|---|
| Price | $18.74 | $13.09 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $21.50 | ★ $31.80 |
| AVG Volume (30 Days) | 268.4K | ★ 1.7M |
| Earning Date | 01-01-0001 | 05-18-2026 |
| Dividend Yield | ★ 8.05% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,539,000.00 |
| Revenue This Year | $7.63 | N/A |
| Revenue Next Year | $2.76 | $965.51 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.07 | $3.91 |
| 52 Week High | $20.25 | $19.11 |
Technical Indicators
Market Signals| Indicator | CTO | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 43.04 | 35.85 |
| Support Level | $17.29 | $11.88 |
| Resistance Level | $19.07 | $14.24 |
| Average True Range (ATR) | 0.38 | 1.16 |
| MACD | -0.13 | -0.42 |
| Stochastic Oscillator | 19.71 | 1.60 |
Price Performance
Historical ComparisonAbout CTO CTO Realty Growth Inc.
CTO Realty Growth Inc is a real estate investment trust company, that owns income properties in diversified markets in the United States. The company operates in four primary business segments: Income properties, management services, commercial loans and investments, and real estate operations. It derives maximum revenue from Income Properties.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses on developing and commercializing innovative therapeutics for serious retinal diseases. It develops therapies for serious retinal diseases to provide durable treatments that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained release product candidate for retinal diseases with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.